All-cause mortality in diabetic patients treated with combinations of sulfonylureas and biguanides

Diabetes/Metabolism Research and Reviews

Volumn 20, Issue 1, 2004, Pages 44-47

  Mannucci, Edoardo ^a   Monami, Matteo ^a   Masotti, Giulio ^a   Marchionni, Niccolò ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Diabetes mellitus; Hypoglycemic treatment; Mortality; Observational study

Indexed keywords

ANTIHYPERTENSIVE AGENT; BIGUANIDE DERIVATIVE; CHLORPROPAMIDE; GLIBENCLAMIDE; HEMOGLOBIN A1C; INSULIN; LIPID; METFORMIN; PHENFORMIN; SULFONYLUREA DERIVATIVE;

ADULT; AGE; AGED; ARTICLE; BODY MASS; CAUSE OF DEATH; CLINICAL OBSERVATION; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE DURATION; DRUG DOSE REGIMEN; DRUG SAFETY; FEMALE; FOLLOW UP; HEMOGLOBIN DETERMINATION; HUMAN; HYPERTENSION; INSULIN TREATMENT; ITALY; LIPID ANALYSIS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT CARE; PRIORITY JOURNAL; REGISTER; RISK ASSESSMENT; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE;

AGED; BIGUANIDES; CAUSE OF DEATH; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; ITALY; MALE; MIDDLE AGED; OUTPATIENTS; RISK; SULFONYLUREA COMPOUNDS;

EID: 1042291960     PISSN: 15207552     EISSN: None     Source Type: Journal    
DOI: 10.1002/dmrr.411     Document Type: Article

References (10)

1. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
2. Fisman EZ, Tenenbaum A, Boyko V, et al. Oral antidiabetic treatment in patients with coronary disease: time-related increased mortality on combined glyburide/metformin therapy over a 7,7-year follow-up. Clin Cardiol 2001; 24: 151-158.
3. Olsson J, Lindberg G, Gottsater M, et al. Increased mortality in type II diabetic patients using sulphonylurea and metformin in combination: a population-based observational study. Diabetologia 2000; 43: 558-560.
4. Harris MI, Hadden WC, Knowler WC, Bennett PH. International criteria for the diagnosis of diabetes and impaired glucose tolerance. Diabetes Care 1985; 8: 562-567.
5. Chalmers J, MacMahon S, Mancia G, et al. World health organization-international society of hypertension guidelines for the management of hypertension. Guidelines sub-committee of the world health organization. Clin Exp Hypertens 1999; 21: 1009-1060.
6. Blackburn H. Classification of the electrocardiogram for population studies: minnesota code. J Electrocardiol 1969; 2: 305-310.
7. Seltzer HS. A summary of criticisms of the findings and conclusions of the university group diabetes program (UGDP). Diabetes 1972; 21: 976-979.
8. Lee TM, Chou TF. Impairment of myocardial protection in type 2 diabetic patients. J Clin Endocrinol Metab 2003; 88: 531-537.
9. Jollis JG, Simpson RJ, Cascio WE, Chowdhury MK, Crouse JR, Smith SC. Relation between sulfonylurea therapy, complications, and outcome for elderly patients with acute myocardial infarction. Am Heart J 1999; 138: S376-S380.
10. Scognamiglio R, Avogaro A, Vigili de Kreutzenberg S, et al. Effects of treatment with sulfonylurea drugs or insulin on ischemia-induced myocardial dysfunction in type 2 diabetes. Diabetes 2002; 51: 808-812.